Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
2018年1月4日 更新者:Washington University School of Medicine
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
The purpose of this research study is to determine the highest dose of a drug called bortezomib that can be given with a drug called G-CSF before stem cell collection to help in the mobilization of stem cells.
研究概览
详细说明
The purpose of this phase I study is to define the maximum tolerated dose of bortezomib and its mobilization effects when given with G-CSF for stem cell mobilization in multiple myeloma patients.
We hypothesize that bortezomib, in addition to increasing the number of mobilized stem cells, will optimize final apheresis product by decreasing myeloma cell contamination.
Therefore, all multiple myeloma patients rather than multiple myeloma patients with G-CSF mobilization failure will be the target of this study.
研究类型
介入性
注册 (实际的)
10
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Missouri
-
Saint Louis、Missouri、美国、63110
- Washington University School of Medicine
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Histologically confirmed diagnosis of multiple myeloma.
- Eligible for autologous transplantation.
- Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-12 months of the first dose of initial therapy.
- At least 18 years of age.
- ECOG performance status ≤ 2
Normal bone marrow and organ function as defined below:
- Platelets ≥ 50,000/mm3
- Hemoglobin ≥ 8.0 g/dL
- Absolute neutrophil count ≥1,000/mm3
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Total bilirubin ≤ 1.5 x IULN
- Measured or calculated creatinine clearance ≥ 30 mL/min
Female patients who:
- are postmenopausal for at least 1 year before the screening visit OR
- are surgically sterile OR
- Women of childbearing potential and men must agree to practice 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Previous stem cell collection or transplantation (autologous or allogeneic).
- Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior to auto-HSCT.
- Diagnosis of plasma cell leukemia.
- Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma or secondary amyloidosis).
- Radiation therapy within 3 weeks prior to enrollment.
- Grade 2 or higher peripheral neuropathy.
- Known hypersensitivity to any of the following: bortezomib, boron, mannitol.
- Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or serious medical or psychiatric illness/social situations that would limit compliance with study requirements.
- Female patients who are pregnant and/or breastfeeding. Patient must have a negative serum pregnancy test within 14 days of study entry.
- Known HIV-positivity. These patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients with HIV-positivity when indicated.
- Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of the trial and throughout the duration of the trial
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1: Dose Level 1 (Bortezomib & G-CSF)
G-CSF will be administered daily for 5 days (Days 1-5).
On Day 4 at approximately 1800 hours, bortezomib will be administered.
Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg.
If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
|
其他名称:
其他名称:
|
|
实验性的:Arm 2: Dose Level 2 (Bortezomib & G-CSF)
G-CSF will be administered daily for 5 days (Days 1-5).
On Day 4 at approximately 1800 hours, bortezomib will be administered.
Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg.
If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
|
其他名称:
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum tolerated dose (MTD) of bortezomib when given with G-CSF
大体时间:Approximately 12 months (completion of all patients on trial)
|
The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first 28 days after administration of the first dose of bortezomib and before auto-HSCT.
Dose escalations will proceed until the MTD has been reached.
|
Approximately 12 months (completion of all patients on trial)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Ghobadi A, Holt M, Ritchey J et al. The effect of Bortezomib (B) Alone or in Combination with Other Agents for Stem Cell Mobilization in Mice. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 583
- Ghobadi A, Fiala MA, Rettig M, Schroeder M, Uy GL, Stockerl-Goldstein K, Westervelt P, Vij R, DiPersio JF. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):e588-e593. doi: 10.1016/j.clml.2019.04.017. Epub 2019 May 2.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2015年2月20日
初级完成 (实际的)
2016年7月31日
研究完成 (实际的)
2016年11月30日
研究注册日期
首次提交
2014年8月15日
首先提交符合 QC 标准的
2014年8月15日
首次发布 (估计)
2014年8月20日
研究记录更新
最后更新发布 (实际的)
2018年1月8日
上次提交的符合 QC 标准的更新
2018年1月4日
最后验证
2018年1月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 201412026
- 1KL2TR002346-01 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.